About this study

Sol-Gel Technologies is currently evaluating an investigational topical product called Patidegib 2% for the prevention of skin cancers in people with Gorlin syndrome.

What’s Required to Participate in Sol-Gel Clinical Study?
Sol-Gel Skin Cancer Clinical Trial

Patidegib 2% Topical Solution for the Prevention of Basal Cell Carcinomas

Those with Gorlin Syndrome face the significant burden of persistently developing skin cancers called basal cell carcinomas (BCCs). Although there are surgical procedures and topical products to treat these skin cancers,
current options are not always adequate for use on the face and no therapies exist to prevent their occurrence. Sol-Gel Technologies is evaluating a topical product called Patidegib 2%.

Basal cell carcinoma is caused by abnormal cell growth in the skin, often linked to overactivity in a biological pathway called the Hedgehog signaling pathway. This pathway is like a communication system that tells cells
when to grow and divide. When it gets out of control, it can lead to cancers like BCC.

Patidegib is suspected to work by blocking this pathway, reducing the likelihood of skin cancer development.

What’s Required to Participate?

To take part in this clinical trial, participants must meet certain criteria including:
Patidegib 2% Topical Solution for the Treatment of Basal Cell Carcinomas

Why Participate?

Participation in this clinical trial can have a big impact on how skin cancers are treated and prevented in those with Gorlin Syndrome. Some benefits you may receive while participating are: